{"id":"insulin-lispro-low-mixture","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro is a recombinant human insulin analog with a rapid onset of action (within 15 minutes) and shorter duration compared to regular human insulin. It mimics the body's natural insulin response to meals by binding to insulin receptors, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. The low mixture formulation combines rapid-acting insulin lispro with intermediate-acting insulin lispro protamine suspension to provide both mealtime and basal glucose control.","oneSentence":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:13.672Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT00664534","phase":"PHASE4","title":"Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00036504","phase":"PHASE4","title":"Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-08","conditions":"Type 2 Diabetes Mellitus","enrollment":100},{"nctId":"NCT00191178","phase":"PHASE4","title":"Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-08","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00551538","phase":"PHASE4","title":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-05","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT00548808","phase":"PHASE4","title":"A Study for Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT00393705","phase":"PHASE4","title":"Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":302},{"nctId":"NCT00420095","phase":"PHASE4","title":"A Study for Patients With Diabetes Mellitus (IOPA)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-01","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY275585[P]"],"phase":"marketed","status":"active","brandName":"Insulin Lispro low mixture","genericName":"Insulin Lispro low mixture","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}